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Abstract
Fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC) reverse oral 
anticoagulants such as Warfarin. We compared the standard dosage of FFP and PCC in terms 
of efficacy and safety for patients with mechanical heart valves undergoing interventional 
procedures while receiving Warfarin. Fifty patients were randomized (25 for each group) 
with mechanical heart valves [international normalized ratio (INR) >2.5]. FFP dosage was 
administered based on body weight (10-15 mL/Kg), while PCC dosage was administered 
based on both body weight and target INR. INR measurements were obtained at different 
time after PCC and FFP infusion. The mean ± SD of INR pre treatment was not significantly 
different between the PCC and FFP groups. However, over a 48-hour period following the 
administration of PCC and FFP, 76% of the patients in the PCC group and only 20% of the 
patients in the FFP group reached the INR target. Five (20%) patients in the PCC group 
received an additional dose of PCC, whereas 17 (68%) patients in the FFP group received a 
further dose of FFP (P=0.001). There was no significant difference between the two groups in 
Hb and Hct before and during a 48-hour period after PCC and FFP infusion. As regards safety 
monitoring and adverse drug reaction screening in the FFP group, the INR was high (INR > 
2.5) in 86% of the patients. There was no report of hemorrhage in both groups. PCC reverses 
anticoagulation both effectively and safely while having the advantage of obviating the need 
to extra doses.
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Introduction
Every year, approximately 300,000 patients 
undergo heart valve surgery worldwide(1). 
Although mechanical heart valves have 
the advantage of a superior durability over 
bioprosthetic valves, they suffer from much 
higher and persistent risk of thromboembolism, 
requiring lifelong anticoagulation therapy. 
Vitamin K antagonists such as Warfarin are the 
existing long-term standards for anticoagulation 
in patients having had cardiac valve replacement 
(2). The risk of Warfarin-induced bleeding 
complications is well known and is typically 
managed with vitamin K, which will restore the 
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of Rajaie Cardiovascular, Medical and Research 
Center, an Iranian tertiary health care hospital. 
Fifty adult patients with mechanical heart valves 
who were admitted to the hospital and provided 
written informed consent were enrolled in the 
present study between July 2012 and February 
2013. All of the patients were undergoing 
interventional procedures while receiving 
Warfarin therapy.
Inclusion and exclusion criteria
The inclusion criteria comprised weight 
under100 Kg, the age between 18-85 years old, 
Warfarin consumption prior to intervention, 
initial international normalized ratio (INR) 
> 2.5, and consumption of FFP or PCC. The 
exclusion criteria were comprised of renal 
or hepatic insufficiency, allergic reaction 
to blood products, past history of Heparin-
induced thrombocytopenia and disseminated 
intravascular coagulation, active thrombosis or 
pulmonary embolism, intracardiac thrombus, 
and pregnancy or breastfeeding.
Treatment
Two treatment groups for the reversal of 
increased INR levels were defined: patients 
treated with PCC (n=25) and those treated with 
FFP (n=25).Vitamin K was never used for the 
patients in either group.
In the PCC group, all the patients were 
given PCC (Uman Complex D.I.) (Kedrion, 
Castelvecchio Pascoli, Italy), which is a 3-factor 
PCC, including factor II, factor IX, and factor X. 
Uman Complex is a lyophilized PCC, which is 
purified human plasma through two ion-exchange 
chromatography steps. Each vial of Uman 
Complex contains a relatively high concentration 
of coagulation factor II (25 IU⁄mL), factor IX (25 
IU⁄mL), factor X (20 IU⁄mL), Heparin (< 12.5 
IU/mL), and antithrombin (< 0.125 IU/mL). The 
PCC administration was based on the patients’ 
body weight (in accordance with relevant INR), 
initial INR, and target INR in keeping with the 
manufacturer’s prescribed individualized dosing 
regimen (Table 1). If the INR was high after the 
initial PCC administration, an additional dose 
was administered.
In the FFP group, FFP was administered 
based on the patients› body weight (10-15 mL/
production of vitamin K-dependent coagulation 
factors within 12-24 hours. It is not, however, 
always feasible to wait for endogenous 
restoration of coagulation factors, especially 
in patients scheduled for either urgent or semi-
urgent coronary artery bypass grafting surgery 
(CABG) involving cardiopulmonary bypass 
(CPB) or valvular surgery in which coumarin 
effects should be reversed rapidly.
Fresh frozen plasma (FFP) and prothrombin 
complex concentrate (PCC) are currently 
deemed suitable for increasing the concentration 
of vitamin K-dependent coagulation factors. 
These two products contain factors II, VII, IX, 
and X and thus help restore normal levels of the 
clotting fraction (3,4).
FFP is human plasma frozen within a specific 
time period after collection both from a donor (5). 
The risks of FFP include disease transmission, 
anaphylactoid reactions, alloimmunization, 
excessive intravascular volume, transfusion-
related acute lung injury, and increased risk of 
infections (6-9).
PCC is derived from pooled, virus-inactivated 
human plasma products and is known to 
provide coagulation factors appropriately and 
rapidly. The majority of PCC products contain 
vitamin K-dependent coagulation factors (II 
[prothrombin],VII, IX, and X), as well as 
therapeutically effective concentrations of 
thrombo inhibitors (protein C and S)(10,11). 
The early PCC composition contained the three 
coagulation factors of II, IX and X, with no or 
very little amount of factor VII. Nevertheless, 
newer formulations, available in some European 
countries, include normal amounts of factor VII 
and are thus known as “four-factor concentrates” 
or “4-factor PCCs” (12).
In this randomized study, we compared the 
efficacy of the infusion of PCC and FFP in 
adult patients with mechanical heart valves who 
were undergoing Warfarin therapy and required 
Warfarin reversal.
Experimental
Study population
This study was conducted in compliance 
with the Helsinki Declaration. The protocol was 
submitted for approval to the Ethics Committee 
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Kg). If the INR was still high following the 
initial FFP administration, additional FFP (JMS 
Singapore PTE, 300 mL) was administered. 
The treatment was provided immediately in an 
emergency setting after block randomization and 
usually before any INR results were available.
Study outcomes
INR measurements were obtained 30 minutes 
after the infusion of FFP and PCC. In both 
groups, serial INR measurements were obtained 
at 4, 8, 12, 16, 20, 24, and 48 hours post PCC 
and FFP infusion. The groups were compared on 
the basis of demographics, units of FFP, units of 
PCC, number of patients achieving INR < 2.5, 
number of patients requiring extra dose(s) of 
each drug to reach the target INR, and adverse 
drug reaction (based on the Kedrion assay of 
adverse drug reaction*) to FFP and PCC. 
Laboratory and clinical assessment
Blood samples were collected for the 
determination of INR prior to infusion and at 
intervals of 0.5, 4, 8, 12, 16, 20, 24, and 48 hours 
as well. Hemoglobin (Hb) and Hematocrit (Hct) 
were determined at baseline and after 48 hours. 
The INR and hematology parameters were 
measured at the laboratory of the study center. 
At enrolment time, all the patients underwent 
a complete clinical assessment, encompassing 
medical history, physical examination, and 
determination of vital signs.
The occurrence of any adverse events, 
including death, thromboembolic complications, 
and allergic reactions, was monitored.
Statistical analysis
The data are presented as mean ± standard 
deviation (SD) for the interval variables and 
count (%) for the categorical variables. The one-
sample Kolmogorov-Smirnov test was applied 
to investigate the fitness of the interval data to 
normal distribution. The clinical outcomes were 
compared between the two groups using the 
Student t-test or the Pearson chi-squared test and 
repeated measure analysis of variance (ANOVA) 
models. A P ≤ 0.05 was considered statistically 
significant. SPSS® 15 for Windows® (SPSS 
Inc., Chicago, Illinois) was utilized for statistical 
analysis.
Results
Between July 2012 and February 2013, a total 
of 50 patients were included and randomized into 
the 3-factor PCC group (n =25) (administered 
according to the INR) and the FFP group (n = 
25) (10-15 mL/Kg).
Out of the 50 patients recruited in our study, 
35 patients were admitted to the Intensive Care 
Unit (ICU) and 15 patients to the Coronary 
Care Unit (CCU). The baseline characteristics 
and demographic data of the study population 
are summarized in Table 2. The overall mean 
(standard deviations (SD)) age was 66.73 ± 
7.81 years, and 56% of the patients were male. 
Patient characteristics did not differ between 
the two groups. All the patients had a history 
of cardiovascular disease, hypertension, and 
valvular surgery. All the patients were under 
treatment with Warfarin sodium.
The types of cardiac surgery in the valvular 
patients are summarized in Table 3.
The INR values before the infusion of PCC 
and FFP were not different between the two 
groups. With respect to efficacy, the INR values 
after treatment were markedly reduced in the 
PCC group. The mean (SD) INR pre treatment 
was 4.02 (1.07) in the PCC group and 4.88 (1.3) 
in the FFP group. 
The INR was measured 15 minutes as well as 
4, 8, 12, 16, 20, 24 and 48 hours after the infusion 
of PCC and FFP. The mean INR value in the PCC 
group was markedly reduced compared with that 
in the FFP group based on serial reporting within 
48 hours of administration. The INR values of 
INR value 2.0-4.0 >4.0 &  <6.0
Dose of PCC to infuse 25 IU/kg 35 IU/kg
Table 1. Recommended uman complex (prothrombin complex concentrate) doses in case of rapid oral anticoagulant therapy reversal*.
*Kedrion Manufacturing Company's recommendation package (insert 2010)
INR, international normalized ratio; PCC, prothrombin complex concentrate
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the PCC and FFP groups are summarized in 
Table 4. The mean INR value in the PCC group 
was markedly reduced compared with that in the 
FFP group based on serial reporting within 48 
hours of administration.
The proportion of the patients who achieved 
the target INR was significantly greater in the 
PCC group (76%) than in the FFP group (20%). 
The total doses of FFP and PCC as well as the 
number of the patients achieving INR < 2.5 are 
demonstrated in Table 5.
Twenty-two of the patients who required 
urgent reversal of oral anticoagulation needed 
additional doses of PCC and FFP to reach 
the target INR: 5 (20%) patients in the PCC 
group and 17 (68%) patients in the FFP group. 
The difference between the two groups was 
statistically significant (P < 005).
There was no significant difference between 
the two groups as regards Hb and Hct before 
and during a 48-hour period after the infusion of 
PCC and FFP.
As for safety monitoring and adverse drug 
reaction screening, none of the patients treated 
with either PCC or FFP suffered hemorrhage, 
although the INR was high (INR > 2.5) in 86% 
of the FFP group.  
In the FFP group, 68% of the patients needed 
All patients PCC FFP P-value
Gender   (n;%)
Male 28 (56) 10 (40%) 18 (72%) 0.73
Female 22 (44) 15 (60%) 7 (28%) 0.74
Age                                    66.73 ± 7.81 65.8 ± 6.79 0.70
Weight                               68.73 ± 9.37 67.47 ± 10.07 0.469
Height                                164.77 ± 6.57 161.73 ± 6.46 <0.01
Heart rate                            97.60 ± 11.08 96.93 ± 10.39 0.75
Systolic BP                          119.87 ± 15.10 123.33 ± 15.88 0.22
Diastolic BP                        72.90 ± 10.26 71.47 ± 11.95 0.46
EF                                       47.50 ± 5.21 48.67 ± 5.16 0.23
Temperature 36.77 ± 0.96 36.93 ± 0.821 019
SGOT                                23.60 ± 10.72 24.73 ± 11.47 0.57
SGPT                                  17.27 ± 11.47 17.07 ± 10.36 093
Creatinine                            1.08 ± 0.29 1.14 ± 0.32 0.31
 Table 2. Baseline demographic and clinical data of the study population.
Data are presented as mean ± SD.Standard Deviation
PCC, prothrombin complex concentrate; FFP, fresh frozen plasma; BP, blood pressure; EF, ejection fraction; SGOT, serum glutamic 
oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase
Type of valve operation FFP (n=25) PCC (n=25)
MVR 3 (12%) 6 (24%)
MVr 4 (16%) 4 (16%)                             
AVR                             3 (12%) 3 (12%)
Aortic valve repair                                                                                                          4 (16%) 4 (16%)
MVR-AVR 4 (16%) 5 (20%)
TVR-MVR                                                          2 (8%) 1 (4%)
MVR-TVR                            2 (8%) 1 (4%)
MVR- AVr- TVR 1 (4%) 0 (0%)
AVR - TVr                                                        2 (8%) 1 (4%)
PCC, prothrombin complex concentrate; FFP, fresh frozen plasma; MVR, mitral valve replacement; AVR, aortic valve replacement; 
TVR, tricuspid valve repair.
Table 3. The types of cardiac surgery in the valvular patients and distributions in patients in the PCC and FFP groups.
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Figure 1. INR fluctuations after PCC & FFP infusion.
Time
INR (mean ±SD)
P-value
PCC (n=25) FFP (n=25)
Pre infusion 4.02 ± 1.07 4.88 ± 1.3 0.07
30 min post infusion 2.34 ± 0.7 3.1 ± 1.04 0.03
4 h post infusion 2.31 ± 0.68 3.11 ± 0.83 1. 23
8 h post infusion 2.43 ± 0.68 3.11 ± 0.83 1.34
12 h post  infusion 2.48 ± 1.03 3.66 ± 1.35 1. 27
16 h post infusion 2.36 ± 0.87 3.7 ± 1.71 0.01
20 h post infusion 2.43 ± 0.75 3.07 ± 1.18 0.09
24 h post infusion 2.64 ± 1.02 2.91 ± 0.88 0.44
48 h post infusion 2.51 ± 0.84 3.35 ± 0.85 0.01
Table 4. INR Variations during the study period.
INR, international normalized ratio; PCC, prothrombin complex concentrate; FFP, fresh frozen plasma
Parameter PCC FFP
FFP units, mean (SD) NA 2.6 (0.507)
PCC total dose, units, mean (SD) 2066.6 (0.34) NA
Patients who achieved INR <2.5, n (%) 19 (76%) 5 (20%)
Table 5. Correlation between prothrombin complex concentrate and fresh frozen plasma dose and reduced target international normalized 
ratio.
FFP, fresh frozen plasma; NA, not applicable; PCC, prothrombin complex concentrate
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Time PCC (n=25) FFP (n=25)
30 min post infusion                               - -
4 h post infusion                             1(4%) -
8 h post infusion                            1(4%) 3(12%)
12 h post infusion                              - 5(20%)
16 h post infusion                           2(8%) 6(24%)
20 h post infusion                              - 3(12%)
24 h post infusion                           1(4%)
48 h post infusion                               - -
Total    (P value 0.001)                                                      5(20%) 17(68%)
Table 6. Extra Doses needed for warfarin reversal by PCC & FFP.
PCC, prothrombin complex concentrate; FFP, fresh frozen plasma.
Hb & Hct Pre & Post Administration PCC (n=25) FFP (n=25) p-value
Hb pre infusion 9.13 ± 1.22 9.48 ± 1.19 0.44
Hb post infusion 9.64 ± 1.7 10.16 ± 1.32 0.36
Hct pre infusion 29.05 ± 4.7 29.68 ± 4.3 0.71
Hct post infusion        30.98 ± 6.6 32.18 ± 4.4 0.57
Table 7. Hemoglobin and Hematocrit fluctuations following PCC & FFP.
Data are presented as mean ± standard deviation.
PCC, prothrombin complex concentrate; FFP, fresh frozen plasma; Hb, hemoglobin; Hct, hematocrit
extra doses. It should be noted that this is not an 
appropriate choice for patients with mechanical 
heart valves and may expose them to the risk of 
volume overload.
Discussion
The present study is the first randomized 
head-to-head comparison between 3-factor 
PCC and FFP as treatment modalities for the 
reversal of Warfarin-induced anticoagulation 
in patients with mechanical heart valves who 
undergo interventional procedures and are at 
risk of bleeding. The main objective of our study 
was the assessment of both efficacy (based on 
the INR) and safety of PCC in patients with 
mechanical heart valves.
Thromboembolic events are the major cause 
of morbidity and mortality in patients with 
mechanical heart valves. Such complications 
can be decreased by oral anticoagulation after 
cardiac surgery (13). The fact that these patients 
are highly susceptible to bleeding under certain 
interventional procedures such as the insertion of 
the intravenous (IV) line or the dialysis catheter 
renders the administration of PCC or FFP in these 
circumstances advisable. PCC is indicated when 
rapid correction of prothrombin complex levels 
is necessary (e.g. major bleeding and emergency 
surgery). In other cases, reducing the dose of 
vitamin K antagonist and/or administrating 
vitamin K is usually sufficient (14).
A) Prothrombin complex concentrate 
indication in expert guidelines
The use of PCC has been advocated for the 
rapid correction of coagulation deficits (15). 
PCC is yet to be recommended by American 
guidelines, reviews, or algorithms (16-19), such 
as the American Heart Association (AHA) or the 
American College of Cardiology (ACC) either in 
cardiac or in non-cardiac surgery. The only hint 
by the AHA is in regard to PCC administration in 
oral anticoagulant therapy of patients with high 
INR, in whom PCC has the advantage of causing 
fewer adverse effects compared with FFP.
However, in European countries, PCC is 
routinely used in addition to or instead of FFP 
(19). A case in point is the guideline by the 
National Health Service (NHS) in 2011, which 
recommends PCC together with vitamin K if 
there is bleeding in patients with prosthetic heart 
valves and high INR. According to the NHS, FFP 
is indicated if PCC is not available (20). Also, the 
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European Society of Cardiology (ESC) in 2005 
published its guideline for valvular heart disease 
and recommended the use of PCC if bleeding 
still continues despite FFP (21). Moreover, 
French guidelines deem PCC superior to FFP in 
reversing major intraoperative bleeding whether 
or not vitamin K is administered (22). Along the 
same lines, the European Medicines Agency’s 
core summary of the product characteristics 
for PCC stipulates that treatment of bleeding 
and perioperative prophylaxis of bleeding in 
acquired deficiency of the prothrombin complex 
coagulation factors are indications for the usage 
of this drug (23). The rationale behind this is that 
clinicians believe that the level of coagulation 
in FFP is relatively low and that the volume of 
FFP required for the correction of coagulopathy 
is too high (19,24). PCC also offers a number of 
advantages over FFP, including lower infusion 
volume, ambient storage, rapid reconstitution, 
immediate availability, lack of blood group 
specificity, and better safety profile (25). 
PCC was first introduced into the Iranian 
Drug Formulary list in 2011 for congenital 
deficiencies of clotting factors in the prothrombin 
complex, bleeding episodes in the presence 
of deficiencies of one or more factors of the 
prothrombin complex, limitations to the use of 
FFP because of the risk of circulatory overload 
or the need for immediate homeostasis, severe 
liver disease with serious bleeding, preparation 
for elective surgery carrying the risk of bleeding 
(e.g. liver transplantation),vitamin K deficiency 
in the presence of life-threatening bleeding, and 
excessive doses of dicoumarols or the need to 
suspend them in emergency conditions (e.g. 
acute hemorrhage and urgent surgery).
B) Efficacy
PCC is more effective to restore the INR 
and facilitate coagulation than is FFP. Our 
results showed that more patients in the PCC 
group reached the desired INR target than in the 
FFP group. The mean INR value prior to PCC 
administration was 4.02 ± 1.07, and the mean 
INR value before FFP administration was 4.88 
± 1.3. However, the mean INR value decreased 
to 2.51 during the first 48-hour period after 
PCC administration, while the mean INR value 
dropped to 3.35 during the first 48-hour period 
following FFP administration (P = 0.01)
 Mendarte L et al. (26) reported that whereas 
the mean INR value prior to PCC administration 
was 2.92 (2.54), the mean INR value after PCC 
was 1.47 (0.44). The mean difference was 1.54 
(2.89), which reached statistical significance (P 
= 0.005). Significance was maintained when 
the general surgery patients were analyzed 
separately (P = 0.001), but that was not the case 
in the cardiac surgery patients (P = 0.36).
Comparative studies have also demonstrated 
that PCC is more effective than is FFP for 
correcting patients’ INRs 
C) Hematocrit and hemoglobin levels
In our study, there was no significant 
difference in Hb and Hct between the two 
groups before and during the first 48-hour period 
following the infusion of PCC and FFP. In a 
similar work by Mendarte L et al., (26) also there 
were no significant differences between Hb and 
Hct before and after PCC.
D) Adverse drug reactions 
In the present study, no major adverse drug 
reactions (e.g. bleeding) were observed directly 
in consequence of PCC administration, which 
can be attributed to the limited sample size of 
the study. Nonetheless, 68% of the patients 
treated with FFP needed extra doses; this is 
not appropriate for patients with valvular heart 
disease because it may render them vulnerable 
to volume overload.
Our results demonstrated that PCC conferred 
more effective reversal of the over coagulated 
patients than did FFP; this can be due to the high 
concentration of coagulation factors in PCC. 
None of the patients treated with either PCC or 
FFP suffered any active bleeding, although the 
FFP group patients were at high risk of bleeding 
because of their high INR levels. 
Thrombotic events have been reported to 
occasionally complicate PPC infusion, but the 
differences in the preparations, dosages (correcting 
the INR to different levels), and patient populations 
in the available reports make it extremely difficult 
to quantify the risk. Thrombogenic effects are very 
likely to vary with different PCC preparations, 
and there is no evidence in the existing literature 
to verify a possible association between PCC and 
thrombosis.   
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Conclusion
In light of our results, PCC is an effective 
and safe alternative to FFP in patients with 
mechanical heart valves. We would, therefore, 
recommend that PCC be employed for rapid 
and effective correction of Warfarin in patients 
with mechanical heart valves who require urgent 
Warfarin reversal.  
The major limitation of the present study is 
its limited sample size, which may have reduced 
the power of trial.
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